inavir royalties, page-19

Worstcase scenario is that Biota related products has a minimum of 41% of the Japanese market for the December Qtr period.

The above assumes GSK reports zero Relenza sales in Japan for that quarter. We'll find out that number on 7 Feb.

While I like the increased royalty rate of Relenza, I wouldnt mind seeing Inavir eating into its market share as well.

We have to think strategically here.... Inavir/LANI is our future.